Cantor Fitzgerald Cuts Price Target on Cypress Sharpridge (CYS) Due to Increased Risks
Get Alerts CYS Hot Sheet
Price: $7.31 --0%
Rating Summary:
2 Buy, 12 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
2 Buy, 12 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Cantor Fitzgerald is maintaining its Buy rating on shares of Cypress Sharpridge (NYSE: CYS) while raising its price target from $13.25 to $12.75 due to increased risks.
The firm notes that the increased risks include, a refinancing wave induced by a new U.S. Government program, drying up of repo lines, a refinancing wave driven by low mortgage rates, and loss of the SEC exemption from the Investment Company Act of 1940.
Due to the company's current dividend yield and the price appreciation of shares, Cantor Fitzgerald believes that now is a good time to buy.
For more ratings news on Cypress Sharpridge click here and for the rating history of Cypress Sharpridge click here.
Shares of Cypress Sharpridge closed at $12.31 yesterday.
The firm notes that the increased risks include, a refinancing wave induced by a new U.S. Government program, drying up of repo lines, a refinancing wave driven by low mortgage rates, and loss of the SEC exemption from the Investment Company Act of 1940.
Due to the company's current dividend yield and the price appreciation of shares, Cantor Fitzgerald believes that now is a good time to buy.
For more ratings news on Cypress Sharpridge click here and for the rating history of Cypress Sharpridge click here.
Shares of Cypress Sharpridge closed at $12.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- USCB Financial Holdings (USCB) Reports Q1, Announces 500K Share Buyback
- Masonite (DOOR) Shareholders Approve Transaction with Owens Corning (OC)
- HOOKIPA Pharma Inc. (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Cantor Fitzgerald, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!